Accelerated Evolution Biotechnologies (AEBi) is a development-stage biopharmaceutical company engaged in the discovery and development of therapeutic peptides. The company has developed an IP-protected combinatorial biology screening platform technology that can be used to find binders to known targets and select the best functional molecules among them. AEBis platform is extremely flexible, harnessing combinatorial biology to discover new and better lead compounds to disease targets. AEBi was incorporated at the Weizmann Institutes ITEK technological incubator in Nes-Tziona, Israel. The company has a collaboration agreement with Israeli biopharmaceutical company Proteologics.